title: IgE immunotherapy against cancer.
abstract: The success of antibody therapy in cancer is consistent with the ability of these molecules to activate immune responses against tumors. Experience in clinical applications, antibody design, and advancement in technology have enabled antibodies to be engineered with enhanced efficacy against cancer cells. This allows re-evaluation of current antibody approaches dominated by antibodies of the IgG class with a new light. Antibodies of the IgE class play a central role in allergic reactions and have many properties that may be advantageous for cancer therapy. IgE-based active and passive immunotherapeutic approaches have been shown to be effective in both in vitro and in vivo models of cancer, suggesting the potential use of these approaches in humans. Further studies on the anticancer efficacy and safety profile of these IgE-based approaches are warranted in preparation for translation toward clinical application.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 54-140, Box 951782, Los Angeles, CA, 90095-1782, USA.
authors.forename: Lai Sum
authors.initials: LS
authors.lastname: Leoh
authors.forename: Tracy R
authors.initials: TR
authors.lastname: Daniels-Wells
authors.forename: Manuel L
authors.initials: ML
authors.lastname: Penichet
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D007167:Immunotherapy; D018396:Mucin-1 / Q000276:immunology; D009369:Neoplasms / Q000628:therapy*; D017430:Prostate-Specific Antigen / Q000276:immunology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D014611:Vaccination
chemical_list: D000906:Antibodies; D007073:Immunoglobulin E; D018396:Mucin-1; D017430:Prostate-Specific Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human